Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies

Eugènia Negredo, Anna Bonjoch, Roger Paredes, Jordi Puig, Bonaventura Clotet

Research output: Contribution to journalArticleResearchpeer-review

22 Citations (Scopus)

Abstract

The effect of therapy with a combination of tenofovir and full-dose didanosine on increases in CD4+ cell count was examined in 2 large trials of treatment-experienced patients with human immunodeficiency virus (HIV) infection (the T-20 versus Optimized Regimen Only [TORO] 1 and 2 clinical trials). Individuals receiving both agents showed little additional increase in CD4+ cell count after week 8 of therapy, whereas those receiving 1 or neither of the agents had continuous increases over a 48-week period. © 2005 by the Infectious Diseases Society of America. All rights reserved.
Original languageEnglish
Pages (from-to)901-905
JournalClinical Infectious Diseases
Volume41
DOIs
Publication statusPublished - 15 Sep 2005

Fingerprint Dive into the research topics of 'Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies'. Together they form a unique fingerprint.

  • Cite this